Evaluation of proinflammatory cytokines and biochemical parameters in patients with advanced‑stage lung cancer: A comparative analysis of different therapeutic approaches

Talab,Tabarak J.; Ali Shafi,Farha A.; Jasim,Saba M.

doi:10.3892/wasj.2025.377

Evaluation of proinflammatory cytokines and biochemical parameters in patients with advanced‑stage lung cancer: A comparative analysis of different therapeutic approaches

Authors:
- Tabarak J. Talab
- Farha A. Ali Shafi
- Saba M. Jasim
View Affiliations

Affiliations: Department of Biology, College of Science, Mustansiriyah University, Baghdad 10061, Iraq, Oncology Teaching Hospital, Medical City Center, Ministry of Health, Baghdad 10015, Iraq
Published online on: July 16, 2025 https://doi.org/10.3892/wasj.2025.377
Article Number: 89
Copyright : © Talab et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunological and biochemical markers play a key role in assessing the therapeutic response of patients with lung cancer and recognizing the adverse effects of cancer therapy on these markers. The present study aimed to elucidate variations within certain proinflammatory cytokines and biochemical levels across several therapeutic approaches at both pre‑ and post‑treatment, providing useful insight that may facilitate the development of more effective and tailored therapy strategies. The present study recruited 120 patients with advanced‑stage lung cancer, who were divided into three groups based on the treatment they received (immunotherapy, chemotherapy or combination therapy). Differences in the levels of certain proinflammatory cytokines (IL‑18 and IFN‑γ) and biochemical parameters [alanine aminotransferase (ALT), aspartate aminotransferase, total serum bilirubin (TSB), creatinine, urea, random blood sugar (RBS)] were evaluated between the pre‑and post‑treatment time points. The results demonstrated that, when comparing between pre‑ and post‑treatment changes, there were a significant elevation in the levels of proinflammatory cytokines in the immunotherapy group (IL‑18, P=0.0090; and IFN‑γ, P<0.0001), with parallel increases observed in the combination group (IL‑18, P=0.0251; and IFN‑γ, P=0.0012). However, in the chemotherapy group, the increase was not significant. By contrast, the level of ALT was significantly decreased in the chemotherapy group (P=0.0133), whilst the TSB level was significantly increased in the combination group post‑treatment, compared with the other groups (P=0.0035). Furthermore, there were significant increases in the levels of creatinine, urea and RBS post‑treatment in the immunotherapy group compared with the other groups (P=0.0019, P=0.0115 and P=0.0088, respectively). On the whole, in the complex field of several therapies designed to eliminate cancer and alleviate its consequences in patients with lung cancer, there is a necessity for a predictive marker to differentiate the varying implications of these treatments on the immunological profile and biochemical parameter levels of patients. The present study highlights the need of evaluating these parameter levels due to their vital involvement in anti‑tumoral effects and potential side‑effects.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol Cancer. 22(40)2023.PubMed/NCBI View Article : Google Scholar
3	Mamdani H, Matosevic S, Khalid AB, Durm G and Jalal SI: Immunotherapy in lung cancer: Current landscape and future directions. Front Immunol. 13(823618)2022.PubMed/NCBI View Article : Google Scholar
4	Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, et al: Predictive biomarkers for immunotherapy in lung cancer: Perspective from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 17:1335–1354. 2022.PubMed/NCBI View Article : Google Scholar
5	Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.PubMed/NCBI View Article : Google Scholar
6	Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
7	Nagy S, Demory Beckler M, Hussein A and Kesselman MM: The development of diabetes and diabetic ketoacidosis following immunotherapy treatment: A systematic review of case reports. Cureus. 16(e57894)2024.PubMed/NCBI View Article : Google Scholar
8	Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E and Melero I: Cytokines in clinical cancer immunotherapy. Br J Cancer. 120:6–15. 2019.PubMed/NCBI View Article : Google Scholar
9	Chaplin DD: Overview of the immune response. J Allergy Clin Immunol. 125 (2 Suppl 2):S3–S23. 2010.PubMed/NCBI View Article : Google Scholar
10	Lan T, Chen L and Wei X: Inflammatory cytokines in cancer: Comprehensive understanding and clinical progress in gene therapy. Cells. 10(100)2021.PubMed/NCBI View Article : Google Scholar
11	Jorgovanovic D, Song M, Wang L and Zhang Y: Roles of IFN-γ in tumor progression and regression: A review. Biomark Res. 8(49)2020.PubMed/NCBI View Article : Google Scholar
12	Alspach E, Lussier DM and Schreiber RD: Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol. 11(a028480)2019.PubMed/NCBI View Article : Google Scholar
13	PDQ Supportive and Palliative Care Editorial Board: Family Caregivers in Cancer: Roles and Challenges (PDQ®). In: PDQ Cancer Information Summaries. National Cancer Institute, Bethesda, 2010.
14	Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J and Giles F: A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 66:25–32. 2017.PubMed/NCBI View Article : Google Scholar
15	Zhao N, Yi Y, Cao W, Fu X, Mei N and Li C: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. Front Oncol. 12(923531)2022.PubMed/NCBI View Article : Google Scholar
16	Zhang C, Mo H, Li M, Wang S, Dou X and Zhang X: The effects of postoperative targeted immunotherapy on peripheral blood cytokines and immune cell profile in lung cancer patients. Front Oncol. 14(1342624)2024.PubMed/NCBI View Article : Google Scholar
17	Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, et al: Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 28:1988–1995. 2017.PubMed/NCBI View Article : Google Scholar
18	Netterberg I, Li C, Molinero L, Budha N, Sukumaran S, Stroh M, Jonsson EN and Friberg LE: A PK/PD analysis of circulating biomarkers and their relationship to tumor response in atezolizumab-treated non-small cell lung cancer patients. Clin Pharmacol Ther. 105:486–495. 2019.PubMed/NCBI View Article : Google Scholar
19	Janho Dit Hreich S, Hofman P and Vouret-Craviari V: The role of IL-18 in P2RX7-mediated antitumor immunity. Int J Mol Sci. 24(9235)2023.PubMed/NCBI View Article : Google Scholar
20	Wang Y, Chen H, Zhang T, Yang X, Zhong J, Wang Y, Chi Y, Wu M, An T, Li J, et al: Plasma cytokines interleukin-18 and CXC motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. Ann Transl Med. 9(33)2021.PubMed/NCBI View Article : Google Scholar
21	Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, et al: IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 583:609–614. 2020.PubMed/NCBI View Article : Google Scholar
22	Savid-Frontera C, Viano ME, Baez NS, Lidon NL, Fontaine Q, Young HA, Vimeux L, Donnadieu E and Rodriguez-Galan MC: Exploring the immunomodulatory role of virtual memory CD8+ T cells: Role of IFN gamma in tumor growth control. Front Immunol. 13(971001)2022.PubMed/NCBI View Article : Google Scholar
23	Chen B, Yang M, Li K, Li J, Xu L, Xu F, Xu Y, Ren D, Zhang J and Liu L: Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer. Oncol Lett. 22(540)2021.PubMed/NCBI View Article : Google Scholar
24	Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, et al: Effect of IL-18 on the expansion and phenotype of human natural killer cells: Application to cancer immunotherapy. Int J Biol Sci. 14:331–340. 2018.PubMed/NCBI View Article : Google Scholar
25	Janho Dit Hreich S, Humbert O, Pacé-Loscos T, Schiappa R, Juhel T, Ilié M, Ferrari V, Benzaquen J, Hofman P and Vouret-Craviari V: Plasmatic inactive IL-18 predicts a worse overall survival for advanced non-small-cell lung cancer with early metabolic progression after immunotherapy initiation. Cancers (Basel). 16(2226)2024.PubMed/NCBI View Article : Google Scholar
26	Jiao J, Li WW, Shang YH, Li XF and Jiao M: Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function. Pakistan J Med Sci. 39:404–408. 2023.PubMed/NCBI View Article : Google Scholar
27	Schoenfeld DA, Djureinovic D, Su DG, Zhang L, Lu BY, Kamga L, Mann JE, Huck JD, Hurwitz M, Braun DA, et al: Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI insight. 10(e184545)2024.PubMed/NCBI View Article : Google Scholar
28	Kessel C, Rossig C and Abken H: Weal and woe of interleukin-18 in the T cell therapy of cancer. J Immunother Cancer. 13(e010545)2025.PubMed/NCBI View Article : Google Scholar
29	Orengo AM, Fabbi M, Miglietta L, Andreani C, Bruzzone M, Puppo A, Cristoforoni P, Centurioni MG, Gualco M, Salvi S, et al: Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int J cancer. 129:1116–1125. 2011.PubMed/NCBI View Article : Google Scholar
30	Parker BS, Rautela J and Hertzog PJ: Antitumour actions of interferons: Implications for cancer therapy. Nat Rev Cancer. 16:131–144. 2016.PubMed/NCBI View Article : Google Scholar
31	Zhang J, Song D, Dong Y, Bai L, Gao D, Zhang S, Guo Y, Li F, Ao M and Li Q: Effects of Chemotherapy on peripheral blood NK cell receptor NKG2D and related immune cytokines in patients with non-small cell lung cancer. J Cancer Ther. 13:631–639. 2022.
32	Feng X, Zhang Z, Sun P, Song G, Wang L, Sun Z, Yuan N, Wang Q and Lun L: Interleukin-18 is a prognostic marker and plays a tumor suppressive role in colon cancer. Dis Markers. 2020(6439614)2020.PubMed/NCBI View Article : Google Scholar
33	Jiang K, Lin B, Zhang Y, Lu K, Wu F and Luo D: A Novel Pyroptosis-Related Gene Signature for Prediction of Disease-Free Survival in Papillary Thyroid Carcinoma. J Pers Med. 13(85)2022.PubMed/NCBI View Article : Google Scholar
34	Nakanishi K: Unique action of interleukin-18 on T cells and other immune cells. Front Immunol. 9(763)2018.PubMed/NCBI View Article : Google Scholar
35	Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X and Li L: IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 143:931–943. 2018.PubMed/NCBI View Article : Google Scholar
36	Burke JD and Young HA: IFN-γ: A cytokine at the right time, is in the right place. Semin Immunol. 43(101280)2019.PubMed/NCBI View Article : Google Scholar
37	Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations associated with acquired resistance to PD-1 blockade in Melanoma. N Engl J Med. 375:819–829. 2016.PubMed/NCBI View Article : Google Scholar
38	Song M, Ping Y, Zhang K, Yang L, Li F, Zhang C, Cheng S, Yue D, Maimela NR, Qu J, et al: Low-dose IFNγ induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer. Cancer Res. 79:3737–3748. 2019.PubMed/NCBI View Article : Google Scholar
39	Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al: Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7:188–201. 2017.PubMed/NCBI View Article : Google Scholar
40	Boutsikou E, Domvri K, Hardavella G, Tsiouda D, Zarogoulidis K and Kontakiotis T: Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: A pragmatic approach in clinical practice. Ther Adv Med Oncol. 10(1758835918768238)2018.PubMed/NCBI View Article : Google Scholar
41	Guo Q, Wu CY, Jiang N, Tong S, Wan JH, Xiao XY, Mei PY, Liu HS and Wang SH: Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma. Front Immunol. 13(986447)2022.PubMed/NCBI View Article : Google Scholar
42	Talab TJ, Shafi FAA and Jasim SM: Association between immune-related adverse events and therapeutic outcomes in patients with advanced non-small cell lung cancer treated with pembrolizumab: A retrospective study. World Acad Sci J. 7:1–9. 2025.
43	Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, Patel S, Patel T, Bramson J, Gupta V, et al: Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study. J Clin Med Res. 11:225–236. 2019.PubMed/NCBI View Article : Google Scholar
44	Casagrande S, Sopetto GB, Bertalot G, Bortolotti R, Racanelli V, Caffo O, Giometto B, Berti A and Veccia A: Immune-related adverse events due to cancer immunotherapy: Immune mechanisms and clinical manifestations. Cancers (Basel). 16(1440)2024.PubMed/NCBI View Article : Google Scholar
45	Grigorian A and O'Brien CB: Hepatotoxicity secondary to chemotherapy. J Clin Transl Hepatol. 2:95–102. 2014.PubMed/NCBI View Article : Google Scholar
46	European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol. 70:1222–1261. 2019.PubMed/NCBI View Article : Google Scholar
47	Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ and Ackland SP: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol. 13:737–741. 2002.PubMed/NCBI View Article : Google Scholar
48	Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, et al: Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 14:4206–4212. 2008.PubMed/NCBI View Article : Google Scholar
49	Smit EF, Mattson K, Von Pawel J, Manegold C, Clarke S and Postmus PE: ALIMTA (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: A phase II study. Ann Oncol. 14:455–460. 2003.PubMed/NCBI View Article : Google Scholar
50	Sakamori Y, Kim YH, Yoshida H, Nakaoku T, Nagai H, Yagi Y, Ozasa H and Mishima M: Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Mol Clin Oncol. 3:334–340. 2015.PubMed/NCBI View Article : Google Scholar
51	Mohammed Bakheet M, Mohssin Ali H and Jalil Talab T: Evaluation of some proinflammatory cytokines and biochemical parameters in pre and postmenopausal breast cancer women. Cytokine. 179(156632)2024.PubMed/NCBI View Article : Google Scholar
52	King PD and Perry MC: Hepatotoxicity of chemotherapy. Oncologist. 6:162–176. 2001.PubMed/NCBI View Article : Google Scholar
53	Guo X, Li W, Hu J, Zhu EC and Su Q: Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: Systematic review and meta-analysis. Eur J Clin Pharmacol. 76:1345–1354. 2020.PubMed/NCBI View Article : Google Scholar
54	Larroquette CA, Hortobagyi GN, Buzdar AU and Holmes FA: Subclinical hepatic toxicity during combination chemotherapy for breast cancer. JAMA. 256:2988–2990. 1986.PubMed/NCBI
55	Huffman BM, Kottschade LA, Kamath PS and Markovic SN: Hepatotoxicity after immune checkpoint inhibitor therapy in Melanoma: Natural progression and management. Am J Clin Oncol. 41:760–765. 2018.PubMed/NCBI View Article : Google Scholar
56	Kwok G, Yau TC, Chiu JW, Tse E and Kwong YL: Pembrolizumab (keytruda). Hum Vaccin Immunother. 12:2777–2789. 2016.PubMed/NCBI View Article : Google Scholar
57	De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, et al: Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 68:1181–1190. 2018.PubMed/NCBI View Article : Google Scholar
58	Zhao P, Yu L, Ma W and Zhao T: Clinical Manifestations and Risk Factors of Liver Injury Induced by PD-1 Inhibitors in Patients with Malignancies: A Case-Control Study. Ther Clin Risk Manag. 21:309–320. 2025.PubMed/NCBI View Article : Google Scholar
59	Tamaki N, Mori N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, et al: Change in liver function in durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma. Anticancer Res. 44:3913–3918. 2024.PubMed/NCBI View Article : Google Scholar
60	Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, Varga A, Malka D, Leary A, Michels J, et al: Renal toxicities associated with pembrolizumab. Clin Kidney J. 12:81–88. 2019.PubMed/NCBI View Article : Google Scholar
61	Xipell M, Victoria I, Hoffmann V, Villarreal J, Garcia-Herrera A, Reig O, Rodas L, Blasco M, Poch E, Mellado B and Quintana LF: Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. Oncoimmunology. 7(e1445952)2018.PubMed/NCBI View Article : Google Scholar
62	Esfahani K, Meti N, Miller WH Jr and Hudson M: Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 191:E40–E46. 2019.PubMed/NCBI View Article : Google Scholar
63	Espi M, Teuma C, Novel-Catin E, Maillet D, Souquet PJ, Dalle S, Koppe L and Fouque D: Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. Eur J Cancer. 147:29–39. 2021.PubMed/NCBI View Article : Google Scholar
64	Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN and Ghosn M: Immune checkpoint inhibitors renal side effects and management. Immunotherapy. 8:1417–1425. 2016.PubMed/NCBI View Article : Google Scholar
65	Borówka M, Łącki-Zynzeling S, Nicze M, Kozak S and Chudek J: Adverse renal effects of anticancer immunotherapy: A review. Cancers (Basel). 14(4086)2022.PubMed/NCBI View Article : Google Scholar
66	Sury K, Perazella MA and Shirali AC: Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol. 14:571–588. 2018.PubMed/NCBI View Article : Google Scholar
67	Waeckerle-Men Y, Starke A and Wüthrich RP: PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant. 22:1527–1536. 2007.PubMed/NCBI View Article : Google Scholar
68	Murakami N, Borges TJ, Yamashita M and Riella LV: Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 9:411–417. 2016.PubMed/NCBI View Article : Google Scholar
69	Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J and Jordan K: ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (suppl 4):iv119–iv142. 2017.PubMed/NCBI View Article : Google Scholar
70	Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 36:1714–1768. 2018.PubMed/NCBI View Article : Google Scholar
71	Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B and Herold KC: Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 38:e55–e57. 2015.PubMed/NCBI View Article : Google Scholar
72	Hansen E, Sahasrabudhe D and Sievert L: A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: Presentation, management and outcome. Cancer Immunol Immunother. 65:765–767. 2016.PubMed/NCBI View Article : Google Scholar
73	Carrero JA, McCarthy DP, Ferris ST, Wan X, Hu H, Zinselmeyer BH, Vomund AN and Unanue ER: Resident macrophages of pancreatic islets have a seminal role in the initiation of autoimmune diabetes of NOD mice. Proc Natl Acad Sci USA. 114:E10418–E10427. 2017.PubMed/NCBI View Article : Google Scholar
74	Schnell PM, Kassem M, Miah A, Ramaswamy B, Williams N, Cherian M, Stover DG, Gatti-Mays ME, Pariser A, Wesolowski R, et al: Changes in glucose level during chemotherapy treatment in patients with stage I-IV breast cancer. Clin Breast Cancer: May 27, 2025 (Epub ahead of print).
75	Fang TZ, Wu XQ, Zhao TQ, Wang SS, Fu GM, Wu QL and Zhou CW: Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma. World J Diabetes. 15:645–653. 2024.PubMed/NCBI View Article : Google Scholar
76	Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar
77	Inzucchi SE and Lupsa B: Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults-UpToDate. https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-initial-evaluation-of-diabetes-mellitusin-adults. 2021.